IDEAYA Showcases Darovasertib Data at ESMO 2026
SOUTH SAN FRANCISCO, Calif., July 17, 2026 IDEAYA Biosciences, Inc. has announced that it will present three clinical abstracts...
antibody drug conjugate
Advertisement
Kelun-Biotech Reports Phase III Success for sac-TMT in NSCLC
CHENGDU, China, July 14, 2026 Kelun-Biotech has announced a major clinical milestone after its Phase III OptiTROP-Lung06 trial evaluating...
Hummingbird Bioscience Wins 2026 APAC AI Trailblazer Award
SINGAPORE, July 14, 2026 Hummingbird Bioscience has been recognized with the prestigious Asia Pacific Trailblazer Award at the 2026...
Hansoh Pharma Reports Positive Phase III Ris-Rez SCLC Results
SHANGHAI, China, July 10, 2026 Hansoh Pharmaceutical Group Co., Ltd. has announced that its Phase III ARTEMIS-008 clinical trial...
Merck Announces Expanded FDA Approval for Keytruda in MIBC
SILVER SPRING, Maryland, July 10, 2026 Merck has received U.S. Food and Drug Administration (FDA) approval for Keytruda® (pembrolizumab)...
Advertisements
Biocytogen Partners Whitehawk on BsADC Cancer Therapies
BOSTON and MORRISTOWN, N.J., July 7, 2026 Biocytogen and Whitehawk Therapeutics have announced a global strategic collaboration to accelerate...
Multitude Therapeutics Reports Positive AMT-676 Phase I Data
SHANGHAI, China, July 2, 2026 Multitude Therapeutics Co., Ltd. announced encouraging interim Phase I clinical results for its CDH17-directed...
ADC Therapeutics Advances ZYNLONTA® in LOTIS-7 Lymphoma Trial
LAUSANNE, Switzerland, June 30, 2026 ADC Therapeutics SA has announced the successful completion of patient enrollment in the LOTIS-7...
Daiichi Sankyo and AstraZeneca Secure EU Enhertu Approval
TOKYO, June 29, 2026 Daiichi Sankyo and AstraZeneca have announced that the European Commission (EC) has approved Enhertu® (trastuzumab...
AstraZeneca, Daiichi Sankyo Advance Datroway Toward EU Approval
CAMBRIDGE, UK & TOKYO, Japan, June 26, 2026 AstraZeneca and Daiichi Sankyo have moved one step closer to expanding...
Advertisement
